[Interstitial lung disease in patients with polymyositis and dermatomyositis--report of three cases]

Małgorzata Bartosiewicz1, Izabela Siemion-Szcześniak, Małgorzata Sobiecka

  • 1I Klinika Chorób Płuc, Instytut Gruźlicy i Chorób Płuc w W arszawie. m.bartosiewicz@igichp.edu.pl.

Insights

Polymyositis and dermatomyositis can cause interstitial lung disease (ILD), a serious complication. Early diagnosis and treatment with corticosteroids, sometimes with other immunosuppressants, lead to good outcomes in patients with PM/DM-ILD.

Area of Science:

  • Rheumatology and Pulmonology
  • Connective Tissue Diseases
  • Interstitial Lung Disease

Background:

  • Polymyositis (PM) and dermatomyositis (DM) are autoimmune connective tissue diseases (CTD) causing muscle weakness and potential organ involvement.
  • Lung complications, including interstitial lung disease (ILD), are frequent in CTD and significantly impact patient prognosis.
  • The pathogenesis of ILD in CTD is not fully understood, but autoimmune processes are implicated.

Observation:

  • Interstitial lung disease (ILD) is the most common lung manifestation in CTD, often preceding or coinciding with myositis symptoms.
  • High-resolution computed tomography (HRCT) is the gold standard for imaging ILD, revealing lung changes with increasing frequency.
  • Three middle-aged men with PM/DM-related ILD presented with varied clinical and radiological findings.

Findings:

  • Histological evaluation revealed non-specific interstitial pneumonitis (NSIP) in two cases and organizing pneumonia with sarcoid changes in one case.
  • All patients exhibited decreased pulmonary function, necessitating treatment.
  • Treatment involved systemic corticosteroids, with two patients receiving additional azathioprine or cyclophosphamide.

Implications:

  • PM/DM-related ILD requires prompt diagnosis and management, often involving a multidisciplinary approach.
  • Systemic corticosteroids are the primary treatment for PM/DM-ILD, with other immunosuppressants used for severe or refractory cases.
  • Effective treatment strategies can lead to favorable outcomes in patients with PM/DM-related ILD.

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
346
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
75
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
4.0K
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
77
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
73
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
497